0:47
Targeting DNA methylation as a therapeutic target in multiple myeloma
Benjamin Barwick
0:52
Therapeutics targeting splicing in hematological malignancies
Omar Abdel-Wahab
3:55
The molecular mechanisms of epigenetic therapies: LTRs and TINATs
Christoph Plass
1:43
The drugs being used to treat newly diagnosed AML patients
Mark Levis
1:41
The future of AML and MDS diagnosis and treatment
Stéphane de Botton
1:02
Bispecific agents: the future of AML and MDS treatment?
John DiPersio
0:52
HARMONY: a collaboration between 51 partners
Lars Bullinger
5:47
Using computational algorithms to predict the response of MDS patients to hypomethylating agents
Aziz Nazha
2:39
Film-coated tablet deferasirox formulation for thalassemia and myelodysplastic syndromes (MDS)
Ali T. Taher
3:16
Recognizing clonal hematopoiesis – diagnostic challenges and clinical relevance
Rafael Bejar
2:24
Advances in acute myeloid leukemia (AML) treatment – updating 7+3
Utz Krug
1:50
Germline predispositions in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)
Jane E. Churpek
1:16
How can the study of familial leukemias help us to understand sporadic leukemias?
Jane E. Churpek
2:17
Oncogenic mutational networks in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS)
Dorit Schneider
3:21
Mode of action of hypomethylating agents for MDS
Valeria Santini
6:01
Treatment of myelodysplastic syndromes (MDS)
Valeria Santini
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

The content of VJHemOnc is intended for healthcare professionals